T1	drug 65 75	antipyrine
T2	drug 80 92	theophylline
T3	pharmacokinetics 93 103	metabolism
T4	pharmacokinetics 245 254	oxidation
T5	drug 258 268	antipyrine
T6	drug 273 285	theophylline
T8	drug 437 447	antipyrine
T9	interaction 448 457	decreased
T11	pharmacokinetics 490 499	half-life
T12	drug 503 515	theophylline
T13	interaction 516 525	decreased
T15	drug 678 688	antipyrine
T16	pharmacokinetics 689 698	half-life
T17	drug 745 757	theophylline
T18	pharmacokinetics 758 767	half-life
T19	pharmacokinetics 818 828	half-lives
T21	pharmacokinetics 870 879	clearance
T22	interaction 1182 1190	increase
T23	interaction 1249 1257	decrease
T24	pharmacokinetics 1359 1376	biotransformation
T25	meal 29 44	dietary protein
T26	meal 49 61	carbohydrate
T27	population 312 331	6 normal volunteers
T28	meal 197 229	dietary carbohydrate and protein
T29	meal 376 411	low carbohydrate-high protein diets
T7	pharmacokinetics 417 433	plasma half-life
A1	valence T9 Diminution
T10	value 463 470	16.2 hr
T30	value 474 480	9.5 hr
A2	valence T13 Diminution
T31	value 531 537	8.1 hr
T32	value 541 547	5.2 hr
T33	meal 591 626	low carbohydrate-high protein diets
T34	meal 632 667	high carbohydrate-low protein diets
T14	interaction 699 708	increased
A3	valence T14 Augmentation
T35	value 714 720	9.5 hr
T36	value 724 731	15.6 hr
T37	interaction 768 777	increased
A4	valence T37 Augmentation
T38	value 783 789	5.2 hr
T39	value 793 800	7.6 hr.
T20	pharmacokinetics 901 933	apparent volumes of distribution
T41	meal 1063 1119	standard diets supplemented with carbohydrate or protein
T42	meal 1121 1171	Supplementing the standard diets with carbohydrate
A5	valence T22 Augmentation
T43	pharmacokinetics 1199 1209	half-lives
T44	meal 1221 1239	protein supplement
A6	valence T23 Diminution
T45	pharmacokinetics 1270 1280	half-lives
T46	population 107 110	man
T47	population 289 292	man
T48	meal 356 372	usual home diets
T49	meal 1032 1046	standard diets
T40	population 1389 1392	man
R3	enzyme_induction Arg1:T33 Arg2:T15	
R4	enzyme_inhibition Arg1:T34 Arg2:T15	
